Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis
NCT ID: NCT01203709
Last Updated: 2014-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
20 participants
INTERVENTIONAL
2010-08-31
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis
NCT00371319
Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus
NCT05916781
Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis
NCT00125307
A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis
NCT00404794
Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis
NCT02630628
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Combination treatment
treatment arm
low dose combination of MMF and Tac
mycophenolate mofetil 500mg BID + tacrolimus 2mg BID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
low dose combination of MMF and Tac
mycophenolate mofetil 500mg BID + tacrolimus 2mg BID
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Failure to respond to 2 or more immunosuppressive regimens which consisted of high-dose prednisolone combined with other non-corticosteroid immunosuppressive agents together with ACE inhibitors plus or minus angiotensin receptor blockers (ARB) for at least 4 months for each regimen at the maximally tolerated drug dosages;
3. Serum creatinine (Scr) less than 200umol/L.
Exclusion Criteria
2. Scr \>200umol/L;
3. Informed consent unavailable.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tuen Mun Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chi Chiu Mok
Consultant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
CC Mok, MD, FRCP
Role: PRINCIPAL_INVESTIGATOR
Tuen Mun Hospital, Hong Kong China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tuen Mun Hospital
Hong Kong, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NTWC/CREC/837/10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.